The Biosimilar Economic Conundrum: Where We Stand

Reimbursement has fallen below acquisition price for some biosimilar versions of infliximab, forcing practices and patients to make difficult decisions. The ACR is working to change this.

Source: The Rheumatologist - January 18, 2024 Category: Rheumatology Authors: Carina Stanton Tags: Insurance Legislation & Advocacy ACR advocacy ACR Insurance Subcommittee (ISC) Biosimilars Source Type: research